AzTrials
AzTrials

NephrolithiasisNCT00149305

Genetic Study of Nephrolithiasis in Gouty Diathesis

An observational study of Nephrolithiasis, run by Mario Negri Institute for Pharmacological Research at 1 site in Italy.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Gouty diathesis describes uric acid or calcium oxalate nephrolithiasis and low urinary pH (<5.5). A hereditary component has been outlined for several forms of nephrolithiasis (such as hypercalciuria, hyperoxaluria, cystinuria, renal tubular acidosis), leading to the hypothesis of a genetic predisposition to… Read more about this study

Who is it for?
Ages 10 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Nephrolithiasis
What is being tested?
Genetic analyses
How many people
37 participants
Where
1 siteItaly
Study dates
May 2005to May 2010
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Unrelated patients with familial form of nephrolithiasis associated with gouty diathesis (at least two affected subjects within a family).

Who may be able to join

  • male and female, ≥ 10 years of age
  • uric acid or calcium oxalate nephrolithiasis
  • urinary 24 h pH < 5.5 in absence of high animal protein intake (urinary sulphate excretion <25 mM/24 h after one week of low animal protein intake)
  • familial history of kidney stones (at least two first or second degree family members affected)
  • written informed consent according to the Declaration of Helsinki guidelines

Who cannot join

  • renal colic in the 4 weeks preceding evaluations
  • excessive gastrointestinal alkali loses
  • inability to fully understand the purposes of the study or to provide a written informed consent

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Clinical Research Center for Rare Diseases

    Ranica, Bergamo, 24020

Other trials in Italy

About this study

Gouty diathesis describes uric acid or calcium oxalate nephrolithiasis and low urinary pH (<5.5). A hereditary component has been outlined for several forms of nephrolithiasis (such as hypercalciuria, hyperoxaluria, cystinuria, renal tubular acidosis), leading to the hypothesis of a genetic predisposition to nephrolithiasis. At the Unit of Nephrology, Ospedali Riuniti di Bergamo, more than 100 patients affected by gouty diathesis are followed. Fifty percent of them has a familiarity for kidney stones formation. The aim of our study is to identify the genetic factors that predispose to the development of nephrolithiasis in patients with gouty diathesis.

Read the detailed description

INTRODUCTION Nephrolithiasis is a common disorder with a reported incidence of 12% in industrialized countries. The peak incidence is in ages 20s to 40s. Men are affected two to three times more often than women. Gouty diathesis describes uric acid or calcium oxalate nephrolithiasis and low urinary pH (<5.5) in the absence of excessive gastrointestinal alkali loses or dietary animal protein excess. Hyperuricemia, hypertriglyceridemia, and a history of gouty arthritis may be present. Subjects with gout are singularly predisposed to stone formation. Persistent acidity of the urine is a common manifestation of primary gout, that may be accompanied by uric acid nephrolithiasis. In the presence of an increase in the concentration of uric acid in the urine, the formation of uric acid stones is further facilitated.

In the primary forms of nephrolithiasis the most important predisposing factors for kidney stones are: hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia, hypomagnesuria, high urinary sulfate, low urine volume, high urinary sodium, cystinuria, infection, persistently high or low urinary pH. A hereditary component has been outlined for several of these abnormalities, leading to the hypothesis of a genetic predisposition to nephrolithiasis. Pirastu and co-workers took advantage from a small, isolated population from Sardinia, characterized by a high prevalence of Uric Acid Nephrolithiasis (UAN). The disease shows familial clustering, although the transmission of UAN does not follow a simple mendelian inheritance pattern, suggesting that hereditary factors could play an important role in susceptibility to UAN. They found an association of UAN to a new gene, called ZNF365, and in particular to its variant Ala62Thr, making it a strong candidate predisposing factor.

At the Unit of Nephrology, Ospedali Riuniti di Bergamo, we follow at the moment 560 patients with nephrolithiasis of which more than 100 are affected by gouty diathesis. 50% of all patients with gouty diathesis has a familiarity for kidney stones formation.

Understanding of the genetic factors that contribute to the development of this disorder may lead to earlier diagnosis, thus allowing to identify, within a family, subjects that are at risk to develop nephrolithiasis before manifestation of the disease. These subjects may have access to counseling aimed at modifying their dietetic and sanitary attitudes and/or to pharmacological treatments in order to prevent the manifestation of the renal disease or to slow its progression.

AIM The study is aimed at identifying the genetic factors that predispose to the development of nephrolithiasis in patients with gouty diathesis.

DESIGN Fifteen consecutive unrelated patients with familial form of nephrolithiasis associated with gouty diathesis (at least two affected subjects within a family) will be recruited, within 3 years, through the stone clinic ambulatory of the Unit of Nephrology, Ospedali Riuniti di Bergamo.

All patients affected by gouty diathesis and their selected relatives will undergo to the following evaluations:

  • clinical history collection;
  • renal ultrasound examination, to confirm previous diagnoses and identify asymptomatic cases;
  • metabolic analyses, including:
  • blood collection in order to evaluate: urate, urea triglycerides, calcium, phosphate, creatinine, bicarbonate, sodium, potassium, chloride, glucose;
  • 24 hours urine collection in order to evaluate urate, calcium, phosphate, oxalate, citrate, urea, magnesium, sodium, chloride, creatinine, sulphate, ammonium; determination of urinary pH and titrable acidity; calculation of acid net excretion;
  • morning urine spot in order to evaluate volume, pH, calcium, uric acid, creatinine;
  • genetic analyses: 10 ml blood on EDTA to obtain DNA and 3 ml without anticoagulant to obtain serum from each subject will be collected.
Conditions
Nephrolithiasis
Being tested
Genetic analyses
Keywords
Gouty diathesis, Acid uric nephrolithiasis
Medical subject headings
Nephrolithiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Genetic analysesOther

  • Genetic analysesOther

Study groups in NCT00149305
Study groupRoleWhat they receive
Patients with gouthy diathesisNot described
Receives: Other: Genetic analyses
Healthy subjectsNot described
Receives: Other: Genetic analyses

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2005 (estimated)
  2. Study startMay 2005
  3. Primary completionJan 2010
  4. Study completionMay 2010

Why it stopped: Non significative preliminary data

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
37 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00149305
Sponsor's protocol ID
GOUTY DIATESIS
Status last verified
Oct 2009
First submitted
7 Sep 2005
Last updated
4 Apr 2023
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Nephrolithiasis, run by Mario Negri Institute for Pharmacological Research at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 4 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Non significative preliminary data). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in